Live Breaking News & Updates on Genome stability group leader

Stay informed with the latest breaking news from Genome stability group leader on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Genome stability group leader and stay connected to the pulse of your community

Pancreatic cancer clinical trial program to target genome an

Date Time
Pancreatic cancer clinical trial program to target genome an
Garvan and UNSW Sydney researchers will establish and lead an innovative pancreatic cancer clinical trial program, thanks to a $3.75 million grant from the Cancer Institute NSW.
A national clinical trial program will test promising new targeted therapy for pancreatic cancer, one of the deadliest forms of cancers of which more than 3000 cases are diagnosed annually in Australia alone.
The clinical trial program (MoST-P), led by researchers and clinicians at UNSW Sydney and the Garvan Institute of Medical Research, will provide patients with access to either targeted therapies matched to the genomic signature of their individual tumour, or targeted to the tumour environment.

Australia , Sydney , New-south-wales , Australians , Australian , Phoebe-phillips , Marina-pajic , David-goldstein , Paul-timpson , David-thomas , Autoimmunity-group , Australian-pancreatic-cancer-foundation